Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri)…
Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.
More settings
Biogen topic overview
The analysis highlights History, Products, Technology and Measurement as prominent areas in the source structure around Biogen.
Related topics
89
Source areas
4
Connected nodes
93
Extracted relationships
117
Concept neighborhoods
20
Bridge connections
93
What this topic covers Research coverage
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
History · 53 topics
Overview · 27 topics
Pipeline · 6 topics
Lawsuits · 3 topics
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
Key facts & relationships
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Founded
1978; 48 years ago (1978)
Founders
Kenneth Murray · Phillip Allen Sharp · Walter Gilbert · Heinz Schaller · Charles Weissmann
Industry
Biotechnology
Headquarters
Cambridge, Massachusetts, U.S.
Formerly
Biogen Idec Inc. (2003–2015)
Key people
Caroline Dorsa (chairman) · Chris Viehbacher (CEO)
Explore all related topics Closing gaps
A structured outline of related entities, concepts and subtopics. Open any item to build a new map centered on it.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
How Biogen connects Entity context
Entity context groups extracted connections by relationship type. Counts show recurrence in the analyzed source; the examples are research signals, not claims about importance.
The extracted context around Biogen shows recurring relationship patterns in the source. For example, Biogen → Acq, Announced, Apellis Pharmaceuticals, Biogen IDECBiogen, Biogen Inc, Biotechnology Geneva, CEO, Charles Weissmann, Chemistry, Convergence Pharmaceuticals, DNA, Edinburgh, Est, Fumapharm AG, Geneva, Gilbert, Harvard University, Heidelberg, Heinz Schaller, HI-Bio Another extracted example is Biogen → Bloomberg, CNV1014802, Convergence Pharmaceuticals, Convergence's, Dow Jones Sustainability World, Elan, Fampyra, In, In February, In January, In October, Index, Isis Pharmaceuticals, On December, Phase II, Tysabri, Under. Use these groups to spot repeated connection types before inspecting the individual relationships.
Biogen → Bloomberg, CNV1014802, Convergence Pharmaceuticals, Convergence's, Dow Jones Sustainability World, Elan, Fampyra, In, In February, In January, In October, Index, Isis Pharmaceuticals, On December, Phase II, Tysabri, Under
related to 2000s· 16
Biogen → After, Biogen Idec, Biotechnology, California-based IDEC Pharmaceuticals, California-San Diego's, Following, Howard Birndorf, In, Ivor Royston, Richard Miller, Robert, Ron Levy, San Diego, Sobol, Stanford University, University
related to Aducanumab· 9
Biogen → Aducanumab, Alzheimer's, In, In December, Later, Neurimmune, Swiss, University, Zurich
Relationships are represented as Subject → Predicate → Object triples. Confidence describes extraction strength, not the real-world importance of a relationship; lower-confidence rows may be contextual rather than explicit.
TTTA extracted 117 structured relationships around Biogen. Examples in this analysis include Biogen → Formerly → Biogen Idec Inc. (2003–2015) and Biogen → Founded → 1978; 48 years ago (1978). The table shows each extracted connection, where it came from and its confidence.
Subject
Predicate
Object
Confidence
Src
Biogen
Formerly
Biogen Idec Inc. (2003–2015)
1.00
infobox
Biogen
Founded
1978; 48 years ago (1978)
1.00
infobox
Biogen
Founders
Kenneth Murray
1.00
infobox
Biogen
Founders
Phillip Allen Sharp
1.00
infobox
Biogen
Founders
Walter Gilbert
1.00
infobox
Biogen
Founders
Heinz Schaller
1.00
infobox
Biogen
Founders
Charles Weissmann
1.00
infobox
Biogen
Headquarters
Cambridge, Massachusetts, U.S.
1.00
infobox
Biogen
Industry
Biotechnology
1.00
infobox
Biogen
Key people
Caroline Dorsa (chairman)
1.00
infobox
Biogen
Key people
Chris Viehbacher (CEO)
1.00
infobox
Biogen
Net income
US$1.29 billion (2025)
1.00
infobox
Biogen
Number of employees
7,500 (2025)
1.00
infobox
Biogen
Operating income
US$1.86 billion (2025)
1.00
infobox
Biogen
Products
Avonex
1.00
infobox
Biogen
Products
Fampyra
1.00
infobox
Biogen
Products
Plegridy
1.00
infobox
Biogen
Products
Tecfidera
1.00
infobox
Biogen
Products
Tysabri
1.00
infobox
Biogen
Products
Spinraza
1.00
infobox
Biogen
Revenue
US$9.89 billion (2025)
1.00
infobox
Biogen
Total assets
US$29.4 billion (2025)
1.00
infobox
Biogen
Total equity
US$18.3 billion (2025)
1.00
infobox
Biogen
Traded as
Nasdaq: BIIB
1.00
infobox
Biogen
Traded as
S&P 500 component
1.00
infobox
Biogen
Type
Public
1.00
infobox
Biogen
Website
biogen.com
1.00
infobox
No triples extracted yet.
Related concept clusters Concept neighborhoods
Concept neighborhoods group terms that sit near one another in the extracted graph. They are useful for discovering adjacent language and context, but proximity does not by itself imply a factual relationship.
The concept neighborhoods around Biogen bring nearby vocabulary together. In this analysis, examples include Announced, Aducanumab and Approval. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
Biogen
Announced
Aducanumab
Approval
Million
Diseases
Inc
Biotechnology
Neurological
March
Pharmaceuticals
Billion
Phase
biogen
Announced
Aducanumab
Approval
Million
Diseases
Inc
Biotechnology
Neurological
March
Pharmaceuticals
Billion
Phase
aducanumab
Alzheimer's
Disease
Approval
Clinical
March
Trials
Fda
Phase
Treatment
Biogen
Two
Announced
cambridge, massachusetts
Massachusetts
Inc
Spinraza
Fampyra
Neurological
Tysabri
Conference
Covid-19
Diseases
First
March
Billion
alzheimer's disease
Disease
Treatment
Two
March
Fda
Approval
Drug
Eisai
Trials
Biogen
First
Phase
multiple sclerosis
Sclerosis
Tysabri
Treatment
Pharmaceuticals
Spinraza
Fampyra
Also
Therapeutics
Acquire
Clinical
Trials
Announced
marketing approval
Fda
Fampyra
Drug
Biogen
Clinical
Eisai
Trials
Disease
Alzheimer's
Phase
Would
March
biotechnology
Cambridge
Massachusetts
First
Inc
Company
Spinraza
Fampyra
Neurological
Tysabri
Diseases
Billion
Phase
Connections between topic areas Semantic bridges
Semantic bridges connect parts of the graph that would otherwise be more separate. A bridge is a structural signal in this analysis, not a claim that the two topic areas are equivalent.
For Biogen, one of the stronger structural bridges in this analysis connects Biogen with History. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
Number of nodes, edges, triples, density and central hubs. Use it to gauge the size and connectivity of the map.
Biogen
Nodes94
Edges93
Triples117
Avg. degree1.98
Density0.021277
Components1
Source & methodology
TTTA analyzes the structure around Biogen to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Products, Technology & Measurement, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
